Keywords: USA, AstraZeneca, Teva, Nexium, Prilosec, Ranbaxy, Dr Reddy's
AstraZeneca settles with Teva over generic Nexium, so avoiding a court battle
Article | 8 January 2010
Anglo-Swedish drug major AstraZeneca has entered into an agreement with Israel-based generics giant Teva Pharmaceutical Industries and its affiliates to settle patent litigation regarding Teva’s proposed generic version of the UK-based firm’s blockbuster gastrointestinal drug Nexium (esomeprazole) delayed-release capsules, which generated global sales of $3.7 billion in the nine months to September 2009.
As part of the settlement, AstraZeneca has granted Teva a license to enter the US market with its generic esomeprazole on May 27, 2014, subject to regulatory approval, or earlier in certain circumstances. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
